The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity
M. J. Kang, E. Hawken, G. Vázquez
Frontiers in Psychiatry April 25, 2022 DOI: 10.3389/fpsyt.2022.860882 (opens in new tab) via Semantic Scholar
Summary
AI-generated from the abstractKetamine's rapid antidepressant effects in major depressive disorder and bipolar disorder, including treatment-resistant depression, may stem from restoring deficits in neuroplasticity. A literature search of 139 publications—from cell cultures, animal models, and patients—found accumulating evidence that ketamine increases molecules involved in neuroplasticity, paired with rapid mood improvements. Key molecules include glutamate, AMPA receptors, mTOR, BDNF/TrkB, VGF, eEF2K, p70S6K, GSK-3, IGF2, Erk, and microRNAs. The studies suggest a robust relationship between mood improvements and ketamine-induced increases in molecular neuroplasticity, especially intracellular signaling molecules.
Study at a glance
| Characteristics | Systematic review Peer reviewed |
|---|---|
| Population | Patients with major depressive disorder or bipolar disorder, including treatment-resistant depression, plus animal models and cell cultures |
| Keywords | Medicine Psychology |
| Key finding | Accumulating evidence supports that ketamine induces increases in molecules involved in modulating neuroplasticity, paired with rapid antidepressant effects. |
Abstract
The mechanism of action underlying ketamine’s rapid antidepressant effects in patients with depression, both suffering from major depressive disorder (MDD) and bipolar disorder (BD), including treatment resistant depression (TRD), remains unclear. Of the many speculated routes that ketamine may act through, restoring deficits in neuroplasticity may be the most parsimonious mechanism in both human patients and preclinical models of depression. Here, we conducted a literature search using PubMed for any reports of ketamine inducing neuroplasticity relevant to depression, to identify cellular and molecular events, relevant to neuroplasticity, immediately observed with rapid mood improvements in humans or antidepressant-like effects in animals. After screening reports using our inclusion/exclusion criteria, 139 publications with data from cell cultures, animal models, and patients with BD or MDD were included (registered on PROSPERO, ID: CRD42019123346). We found accumulating evidence to support that ketamine induces an increase in molecules involved in modulating neuroplasticity, and that these changes are paired with rapid antidepressant effects. Molecules or complexes of high interest include glutamate, AMPA receptors (AMPAR), mTOR, BDNF/TrkB, VGF, eEF2K, p70S6K, GSK-3, IGF2, Erk, and microRNAs. In summary, these studies suggest a robust relationship between improvements in mood, and ketamine-induced increases in molecular neuroplasticity, particularly regarding intracellular signaling molecules.